Varian Halcyon Treatment System Receives Taiwan FDA Approval
PALO ALTO, Calif., Jan. 8, 2018 -- (Healthcare Sales &Marketing Network) -- Varian (NYSE: VAR) today announced its Halcyon system has received Taiwan FDA approval, which allows the company to market this new cancer treatment system in Taiwan. This appr... Devices, Oncology, Regulatory Varian Medical Systems, Halcyon, IMRT, radiotherapy
Publication date: January 2020Source: Radiation Physics and Chemistry, Volume 166Author(s): Fang-Yu Liu, Zhi-Wei Dong, Hui-Bin Yang, Hong-Yun ShiAbstractEven with advanced inverse intensity modulated radiation therapy (IMRT) technique, the optimization of treatment plans remains a time-consuming task and the outcome is highly influenced by the experience of the planner and time pressure. Automated treatment planning is a current hot topic and new frontier in radiotherapy, which is expected to minimize the above problems. The quality and efficacy of the IMRT plans generated by the Auto-Planning module of the Pinnacle3 treat...
ConclusionThis survey was an informative trial to understand the verification status of patient-specific IMRT QA measurements for prostate cancer. In most institutions, the point dose measurement and dose distribution differences met the desired criteria.
Conclusions: We describe here the first report of a potential abscopal effect in meningioma, summarize the limited literature on the topic of abscopal effects in cancer, and detail the existing hypothesis on how this phenomenon may occur and possibly relate to the development of future treatments for patients with metastatic disease.
ConclusionUsing robust optimization for skin flash in breast IMRT planning is feasible. Further investigation is warranted to confirm the clinical effectiveness of this novel approach.
Intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) are standard physical technologies of stereotactic body radiotherapy (SBRT) that are used for patients with non-small-cell lu...
Conditions: Oropharynx Cancer; Oropharynx Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma; Oropharyngeal Neoplasms; Neoplasms, Squamous Cell; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Pharyngeal Neoplasms Malignant and Unspecif ied; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Otorhinolaryngologic Diseases; Pharyngeal Diseases...
CONCLUSION: The overexpression of p53 and eIF4E in pathologically negative margins may represent a subset of patients who would benefit from early initiation of adjuvant radiation and tailored intensity-modulated radiotherapy (IMRT).
Conclusion: IMRT-based CCRT resulted in higher survival rates in patients with advanced clinical stages of TESCC (i.e., IIIA–IIIC), namely, clinical T3, clinical T4, or lymph node involvement.
TORPEdO (TOxicity Reduction using Proton bEam therapy for Oropharyngeal cancer) is the UK's first proton clinical trial. It is a multicentre phase III trial of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated radiotherapy (IMRT) for oropharyngeal squamous cell carcinoma (OPSCC).